Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Tenorio CH, Sequera S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Iglesias HA, Javier R, Ruz MÁ, Romero A, Vallecillos CG. Tenorio CH, et al. Among authors: ryan p. Int J Antimicrob Agents. 2024 Apr 2:107164. doi: 10.1016/j.ijantimicag.2024.107164. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38574873 Free article.
Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).
Pérez Elías MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, García-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo García MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepúlveda MA, Troya J, Del Campo S, Martinez E; CODAR study group. Pérez Elías MJ, et al. J Antimicrob Chemother. 2019 Oct 1;74(10):3044-3048. doi: 10.1093/jac/dkz254. J Antimicrob Chemother. 2019. PMID: 31236601
Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016.
Perez Valero I, Cabello A, Ryan P, De La Fuente-Moral S, Santos I, Vivancos MJ, Gonzalez A, Gorgolas M, Cuevas G, Diaz De Santiago A, Cano J, Rua G, Yllescas M, González García JJ. Perez Valero I, et al. Among authors: ryan p. Open Forum Infect Dis. 2020 Oct 18;7(12):ofaa482. doi: 10.1093/ofid/ofaa482. eCollection 2020 Dec. Open Forum Infect Dis. 2020. PMID: 33335931 Free PMC article.
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Jiménez de Ory S, Beltrán-Pavez C, Gutiérrez-López M, Santos MDM, Prieto L, Sainz T, Guillen S, Aguilera-Alonso D, Díez C, Bernardino JI, Mellado MJ, Ramos JT, Holguín Á, Navarro M; Paediatric Cohort of the Spanish National AIDS Network (CoRISpe and CoRISpe-FARO). Jiménez de Ory S, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1886-1892. doi: 10.1093/jac/dkab080. J Antimicrob Chemother. 2021. PMID: 33734374 Free PMC article.
Integrase inhibitors in children and adolescents: clinical use and resistance.
Torres-Fernandez D, Jiménez de Ory S, Fortuny C, Sainz T, Falcón D, Bernal E, Jiménez MC, Vilasaró MN, Epalza C, Navarro M, Ramos JT, Holguín Á, Prieto L; CoRIS and CoRISpe Spanish National Cohorts, CoRISpe and CoRISpe-FARO Cohort Working Group. Torres-Fernandez D, et al. J Antimicrob Chemother. 2022 Sep 30;77(10):2784-2792. doi: 10.1093/jac/dkac259. J Antimicrob Chemother. 2022. PMID: 35971971
Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid.
Martín-Carbonero L, Gutierrez Á, Bisbal O, Vergas J, González-Baeza A, Rodríguez Martín C, Vivancos MJ, Sanz J, Álvarez B, Palomar M, de Los Santos I, Sepúlveda-Crespo D, Resino S, Berenguer J, Cano-Smith J, González-García J, Ryan P. Martín-Carbonero L, et al. Among authors: ryan p. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Nov 7:S2529-993X(23)00258-7. doi: 10.1016/j.eimce.2023.06.011. Online ahead of print. Enferm Infecc Microbiol Clin (Engl Ed). 2023. PMID: 37945463
Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.
Perez Elias MJ, Alejos B, Gutierrez MM, Crespo M, De Los Santos Gil I, Ribera E, Galindo MJ, Lozano F, Payeras Cifre A, Boix V, Montero-Alonso M, Sanz J, De La Torre Lima J, Palacios R, De La Fuente Moral S, Martinez E; Codar Study Group. Perez Elias MJ, et al. J Antimicrob Chemother. 2021 Mar 12;76(4):1046-1050. doi: 10.1093/jac/dkaa547. J Antimicrob Chemother. 2021. PMID: 33501995
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score.
Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I, Carratalà J, Pachón J, Carcas AJ, Yllescas M, Arribas JR; COVID-19@Spain and COVID@HULP Study Groups. Berenguer J, et al. Among authors: ryan p. Thorax. 2021 Sep;76(9):920-929. doi: 10.1136/thoraxjnl-2020-216001. Epub 2021 Feb 25. Thorax. 2021. PMID: 33632764 Free PMC article.
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group. Arribas JR, et al. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062880 Clinical Trial.
2,484 results